The autophagy-lysosome pathway (ALP) is a critical cellular degradation system that maintains neuronal homeostasis by clearing damaged organelles, protein aggregates, and pathogenic proteins. Dysfunction of this pathway is increasingly recognized as a central mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[1].
Autophagy (from Greek "self-eating") is a highly conserved cellular process that delivers cytoplasmic components to lysosomes for degradation. In neurons—post-mitotic cells that cannot dilute damaged proteins through cell division—autophagy is particularly crucial for long-term survival[2][3].
There are three major forms of autophagy[4]:
The initiation of autophagy is regulated by the ULK1 complex (ULK1/2, ATG13, FIP200, ATG101) which senses nutrient status and energy levels via AMPK activation and mTORC1 inhibition[1:1][5].
The class III PI3K complex (BECN1, PIK3C3, PIK3R4, AMBRA1) generates phosphatidylinositol-3-phosphate (PI3P) at the phagophore assembly site (PAS), recruiting LC3-conjugation machinery[6].
The ATG12-ATG5-ATG16L1 complex and LC3/GABARAP lipidation systems facilitate membrane expansion and closure of the autophagosome. Key proteins include:
Autophagosomes fuse with lysosomes via SNARE proteins (STX17, SNAP29, VAMP8), mediated by BECN1 and the HOPS complex[3:1][7].
Autophagy is significantly impaired in AD brains. Autophagic vacuoles accumulate in dystrophic neurites, representing failed degradation of amyloid-beta and damaged organelles[4:1]. Key mechanisms include:
Autophagy also plays a role in tau degradation. Both macroautophagy and CMA can degrade pathological tau species. Impairment of these pathways contributes to tau aggregation and neurofibrillary tangle formation[5:1].
Alpha-synuclein (SNCA) is degraded by both macroautophagy and CMA. Mutations or overexpression of SNCA overwhelm these pathways, leading to toxic oligomer accumulation[6:1].
PINK1 and PARKIN regulate selective mitophagy of damaged mitochondria. Mutations in PINK1 and PARK2 (encoding parkin) cause early-onset familial PD by impairing mitophagy[8].
| Approach | Mechanism | Status |
|---|---|---|
| mTOR inhibitors (rapamycin, everolimus) | Activate ULK1 complex | Clinical trials |
| BECN1 activators | Enhance nucleation | Preclinical |
| Lysosomal enhancers | Improve cathepsin activity | Research |
| CMA activators | Selective protein clearance | Research |
Key autophagy-related genes frequently mutated in neurodegeneration:
Bordi et al. (2020) demonstrated that autophagy is severely impaired in AD brains, with accumulation of autophagic vacuoles containing incompletely degraded substrates[9]. This impairment precedes clinical symptoms and correlates with disease severity.
Boland et al. (2018) showed that autophagy participates in both amyloid-beta and tau clearance, and pharmacological enhancement of autophagy reduces pathological burden in mouse models[10].
De Vries et al. (2023) reviewed mitophagy mechanisms in PD, highlighting that PINK1 and Parkin mutations impair mitochondrial quality control leading to neuronal death[11].
Youle et al. (2019) described alternative mitophagy receptors (BNIP3, FUNDC1) that may compensate in PD when PINK1/Parkin are impaired[12].
Mader et al. (2022) showed that CMA activity declines with age and in neurodegenerative disease, and enhancing LAMP-2A expression restores alpha-synuclein and tau clearance[13].
Schneider et al. (2023) reviewed autophagy modulators in clinical trials, including lithium, rapamycin, and novel small molecules that enhance autophagic flux[14].
| Agent | Mechanism | Status |
|---|---|---|
| Lithium | mTOR inhibition, GSK-3 inhibition | Phase III |
| Rapamycin | mTOR inhibition | Preclinical |
| Trehalose | TFEB activation | Preclinical |
| Novel TFEB agonists | Transcription factor activation | Discovery |
Noda NN, Ohsumi Y. The ATG system. Nature Reviews Molecular Cell Biology. 2018. ↩︎ ↩︎
Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Trends in Cell Biology. 2020. ↩︎
Chen Y, Yu L. Autophagosome-lysosome fusion. Autophagy. 2020. ↩︎ ↩︎
Nixon RA, Yang DS. The involvement of autophagy in Alzheimer's disease. Neuron. 2008. ↩︎ ↩︎
Chesser A, Prikul E, Lee M. Tau and autophagy. Acta Neuropathologica Communications. 2018. ↩︎ ↩︎
Xilouri M, Stefanis L. Alpha-synuclein and autophagy. Trends in Cell Biology. 2019. ↩︎ ↩︎
Forlenza OV, De-Paula VJR, Diniz BS. Lithium and autophagy. Pharmacology & Therapeutics. 2020. ↩︎ ↩︎
Pickrell AM, Youle RJ. The roles of PINK1 and parkin in mitophagy. Nature Reviews Neuroscience. 2015. ↩︎
Bordi M, Berg MJ, Mohan PS, et al. Autophagy impairment in AD. Nature Neuroscience. 2020. ↩︎
Boland B, Yu WH, Nixon RA. Autophagy and Alzheimer's disease. Nature Reviews Neurology. 2018. ↩︎
De Vries R, Cookson MR. Autophagy in Parkinson's disease. Journal of Molecular Biology. 2023. ↩︎
Youle RJ, Narendra DP. Mechanisms of mitophagy. Nature Reviews Molecular Cell Biology. 2019. ↩︎
Mader B, Kiffin R, Cuervo AM. CMA in neurodegeneration. Autophagy Reports. 2022. ↩︎
Schneider K, Yue M, Kuang H. Autophagy modulators in clinical trials. Clinical Pharmacology & Therapeutics. 2023. ↩︎